Recombinant Plasmid miRNA Composition for Androgen Receptor Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bioactive molecules such as the androgen receptor are often over-expressed or mis-expressed, leading to loss of homeostasis and resulting in disease or undesirable physical manifestations, necessitating therapies to correct this misregulation.
Innovation Solution
Compositions comprising recombinant plasmids that encode for micro-interfering ribonucleic acid (miRNA) sequences are administered to upregulate miRNA production, which target and degrade or inactivate the mRNA of the androgen receptor, thereby reducing its expression and restoring homeostasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bioactive molecules such as androgen receptor are over-expressed or mis-expressed, then disease or undesirable physical manifestations occur, but homeostasis is lost
Solution Approach 1:
The patent converts the harmful effect of over-expressed androgen receptor into a beneficial therapeutic outcome by using miRNA molecules that specifically target and suppress the androgen receptor mRNA. The miRNA-543 expression cassette is designed to bind to the androgen receptor mRNA sequence, preventing its translation and effectively reducing the harmful over-expression to restore homeostasis.
Solution Approach 2:
The patent introduces miRNA-543 as an intermediary molecule that mediates between the androgen receptor gene and the protein production process. The miRNA acts as a regulatory intermediary that binds to the androgen receptor mRNA and prevents its translation, thereby controlling the quantity of androgen receptor protein without directly modifying the gene itself.
2Reliability
If miRNA production is upregulated to decrease target biomolecule bioavailability, then disease is ameliorated, but the complexity of the composition increases
Solution Approach 1:
The patent employs a nested structure where the miRNA-543 expression cassette is inserted within the backbone sequence of a recombinant plasmid. The expression cassette contains the miRNA coding sequence flanked by regulatory elements (promoter, terminator), which are themselves nested within the plasmid structure. This nested organization allows for efficient gene expression while maintaining a manageable composition structure.
Solution Approach 2:
The patent divides the recombinant plasmid composition into distinct functional segments: the backbone sequence containing essential plasmid elements (origin of replication, antibiotic resistance), and the insert sequence containing the miRNA-543 expression cassette with its own promoter and terminator regions. This segmentation allows for modular construction and optimization of the therapeutic composition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively decrease the bioavailability of the androgen receptor, ameliorating the associated diseases by increasing miRNA production, which leads to a decrease in the target biomolecule's production and functionality.
Implementation Method 1
the sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for the translation of a target biomolecule, and the miRNA can cause the bioavailability of the target mRNA to decrease because it is degraded or inactivated by the miRNA
Data Source
AI summary
The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid (RP) and one or more sequences of micro-interfering ribonucleic acid (miRNA). When the RP interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a nuclear receptor. In some embodiments of the present disclosure, the nuclear receptor is the androgen receptor.